Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

Also called NCT02561130

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 154 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02561130
Other papers using this trial's data
  • Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin The Journal of clinical endocrinology and metabolism, 2020-08-01 DOI, PubMed 32403130

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02561130. Randomized; no masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2017-07 (actual). Results posted on 2020-11-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
insulin glargine
Intervention (Drug)
metformin
Intervention (Drug)
Forxiga
Intervention (Behavioral)
Lifestyle therapy
Lead sponsor
Population Health Research Institute (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02561130
Content hash
7e452af9e88b4e47501bfa4925d41869fc608d15d6166b10d639b0401a004618